Cargando…

Mechanistic and Single-Dose In Vivo Therapeutic Studies of Cry5B Anthelmintic Action against Hookworms

BACKGROUND: Hookworm infections are one of the most important parasitic infections of humans worldwide, considered by some second only to malaria in associated disease burden. Single-dose mass drug administration for soil-transmitted helminths, including hookworms, relies primarily on albendazole, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yan, Zhan, Bin, Keegan, Brian, Yiu, Ying Y., Miller, Melanie M., Jones, Kathryn, Aroian, Raffi V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493396/
https://www.ncbi.nlm.nih.gov/pubmed/23145203
http://dx.doi.org/10.1371/journal.pntd.0001900
_version_ 1782249259889852416
author Hu, Yan
Zhan, Bin
Keegan, Brian
Yiu, Ying Y.
Miller, Melanie M.
Jones, Kathryn
Aroian, Raffi V.
author_facet Hu, Yan
Zhan, Bin
Keegan, Brian
Yiu, Ying Y.
Miller, Melanie M.
Jones, Kathryn
Aroian, Raffi V.
author_sort Hu, Yan
collection PubMed
description BACKGROUND: Hookworm infections are one of the most important parasitic infections of humans worldwide, considered by some second only to malaria in associated disease burden. Single-dose mass drug administration for soil-transmitted helminths, including hookworms, relies primarily on albendazole, which has variable efficacy. New and better hookworm therapies are urgently needed. Bacillus thuringiensis crystal protein Cry5B has potential as a novel anthelmintic and has been extensively studied in the roundworm Caenorhabditis elegans. Here, we ask whether single-dose Cry5B can provide therapy against a hookworm infection and whether C. elegans mechanism-of-action studies are relevant to hookworms. METHODOLOGY/PRINCIPAL FINDINGS: To test whether the C. elegans invertebrate-specific glycolipid receptor for Cry5B is relevant in hookworms, we fed Ancylostoma ceylanicum hookworm adults Cry5B with and without galactose, an inhibitor of Cry5B-C. elegans glycolipid interactions. As with C. elegans, galactose inhibits Cry5B toxicity in A. ceylanicum. Furthermore, p38 mitogen-activated protein kinase (MAPK), which controls one of the most important Cry5B signal transduction responses in C. elegans, is functionally operational in hookworms. A. ceylanicum hookworms treated with Cry5B up-regulate p38 MAPK and knock down of p38 MAPK activity in hookworms results in hypersensitivity of A. ceylanicum adults to Cry5B attack. Single-dose Cry5B is able to reduce by >90% A. ceylanicum hookworm burdens from infected hamsters, in the process eliminating hookworm egg shedding in feces and protecting infected hamsters from blood loss. Anthelmintic activity is increased about 3-fold, eliminating >97% of the parasites with a single 3 mg dose (∼30 mg/kg), by incorporating a simple formulation to help prevent digestion in the acidic stomach of the host mammal. CONCLUSIONS/SIGNIFICANCE: These studies advance the development of Cry5B protein as a potent, safe single-dose anthelmintic for hookworm therapy and make available the information of how Cry5B functions in C. elegans in order to study and improve Cry5B function against hookworms.
format Online
Article
Text
id pubmed-3493396
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-34933962012-11-09 Mechanistic and Single-Dose In Vivo Therapeutic Studies of Cry5B Anthelmintic Action against Hookworms Hu, Yan Zhan, Bin Keegan, Brian Yiu, Ying Y. Miller, Melanie M. Jones, Kathryn Aroian, Raffi V. PLoS Negl Trop Dis Research Article BACKGROUND: Hookworm infections are one of the most important parasitic infections of humans worldwide, considered by some second only to malaria in associated disease burden. Single-dose mass drug administration for soil-transmitted helminths, including hookworms, relies primarily on albendazole, which has variable efficacy. New and better hookworm therapies are urgently needed. Bacillus thuringiensis crystal protein Cry5B has potential as a novel anthelmintic and has been extensively studied in the roundworm Caenorhabditis elegans. Here, we ask whether single-dose Cry5B can provide therapy against a hookworm infection and whether C. elegans mechanism-of-action studies are relevant to hookworms. METHODOLOGY/PRINCIPAL FINDINGS: To test whether the C. elegans invertebrate-specific glycolipid receptor for Cry5B is relevant in hookworms, we fed Ancylostoma ceylanicum hookworm adults Cry5B with and without galactose, an inhibitor of Cry5B-C. elegans glycolipid interactions. As with C. elegans, galactose inhibits Cry5B toxicity in A. ceylanicum. Furthermore, p38 mitogen-activated protein kinase (MAPK), which controls one of the most important Cry5B signal transduction responses in C. elegans, is functionally operational in hookworms. A. ceylanicum hookworms treated with Cry5B up-regulate p38 MAPK and knock down of p38 MAPK activity in hookworms results in hypersensitivity of A. ceylanicum adults to Cry5B attack. Single-dose Cry5B is able to reduce by >90% A. ceylanicum hookworm burdens from infected hamsters, in the process eliminating hookworm egg shedding in feces and protecting infected hamsters from blood loss. Anthelmintic activity is increased about 3-fold, eliminating >97% of the parasites with a single 3 mg dose (∼30 mg/kg), by incorporating a simple formulation to help prevent digestion in the acidic stomach of the host mammal. CONCLUSIONS/SIGNIFICANCE: These studies advance the development of Cry5B protein as a potent, safe single-dose anthelmintic for hookworm therapy and make available the information of how Cry5B functions in C. elegans in order to study and improve Cry5B function against hookworms. Public Library of Science 2012-11-08 /pmc/articles/PMC3493396/ /pubmed/23145203 http://dx.doi.org/10.1371/journal.pntd.0001900 Text en © 2012 Hu et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Hu, Yan
Zhan, Bin
Keegan, Brian
Yiu, Ying Y.
Miller, Melanie M.
Jones, Kathryn
Aroian, Raffi V.
Mechanistic and Single-Dose In Vivo Therapeutic Studies of Cry5B Anthelmintic Action against Hookworms
title Mechanistic and Single-Dose In Vivo Therapeutic Studies of Cry5B Anthelmintic Action against Hookworms
title_full Mechanistic and Single-Dose In Vivo Therapeutic Studies of Cry5B Anthelmintic Action against Hookworms
title_fullStr Mechanistic and Single-Dose In Vivo Therapeutic Studies of Cry5B Anthelmintic Action against Hookworms
title_full_unstemmed Mechanistic and Single-Dose In Vivo Therapeutic Studies of Cry5B Anthelmintic Action against Hookworms
title_short Mechanistic and Single-Dose In Vivo Therapeutic Studies of Cry5B Anthelmintic Action against Hookworms
title_sort mechanistic and single-dose in vivo therapeutic studies of cry5b anthelmintic action against hookworms
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493396/
https://www.ncbi.nlm.nih.gov/pubmed/23145203
http://dx.doi.org/10.1371/journal.pntd.0001900
work_keys_str_mv AT huyan mechanisticandsingledoseinvivotherapeuticstudiesofcry5banthelminticactionagainsthookworms
AT zhanbin mechanisticandsingledoseinvivotherapeuticstudiesofcry5banthelminticactionagainsthookworms
AT keeganbrian mechanisticandsingledoseinvivotherapeuticstudiesofcry5banthelminticactionagainsthookworms
AT yiuyingy mechanisticandsingledoseinvivotherapeuticstudiesofcry5banthelminticactionagainsthookworms
AT millermelaniem mechanisticandsingledoseinvivotherapeuticstudiesofcry5banthelminticactionagainsthookworms
AT joneskathryn mechanisticandsingledoseinvivotherapeuticstudiesofcry5banthelminticactionagainsthookworms
AT aroianraffiv mechanisticandsingledoseinvivotherapeuticstudiesofcry5banthelminticactionagainsthookworms